The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Pigment Cell Melanoma Res. 2023 Dec 29. doi: 10.1111/pcmr.13156. Online ahead of print.ABSTRACTDacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent therapies. The aim of this study was to investigate the treatment effect of DTIC/TMZ in MM patients after CPI therapy in a consecutive patient cohort and through systematic literature revie...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Viktoria Ryd én Ali Inan El-Naggar Anthoula Koliadi Cecilia Olsson Ladjevardi Evangelos Digkas Antonios Valachis Gustav J Ullenhag Source Type: research
Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study
This study reviewed 26 PMME cases from three medical centers. Hybrid capture-based targeted sequencing of 295 and 1021 genes was performed in 14 and 12 cases, respectively. We found that PMME patients had a relatively low tumor mutation burden (median, 2.88 mutations per Mb) and were simultaneously accompanied by mutations in genes such as KIT (6/26, 23%), TP53 (6/26, 23%), SF3B1 (4/26, 15%), and NRAS (3/26, 12%). KIT, NRAS, and BRAF were mutually exclusive, and SF3B1 co-occurred with KIT mutation and amplification. The most common pathways affected were the mitogen-activated protein kinases and DNA damage response (DDR) p...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Ling Deng Hai-Yun Wang Chun-Fang Hu Xiao-Yun Liu Kuntai Jiang Juan-Juan Yong Xiao-Yan Wu Kai-Hua Guo Fang Wang Source Type: research
Small extracellular vesicle-based human melanocyte and melanoma signature
Pigment Cell Melanoma Res. 2023 Dec 29. doi: 10.1111/pcmr.13158. Online ahead of print.ABSTRACTIntercellular communication is a cell-type and stimulus-dependent event driven not only by soluble factors but also by extracellular vesicles (EVs). EVs include vesicles of different size and origin that contain a myriad of molecules. Among them, small EVs (sEV; <200 nm) have been shown to modulate not just regional cell responses but also distant organ behavior. In cancer, distant organ modulation by sEVs has been associated to disease dissemination, which is one of the main concerns in melanoma. Description of broadly conser...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Andrea Ag üera-Lorente Ainhoa Alonso-Pardavila Mar ía Larrinaga Mar ía Dolores Boyano Esperanza Gonz ález Juan Manuel Falc ón-Pérez Aintzane Asumendi Aintzane Apraiz Source Type: research
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Pigment Cell Melanoma Res. 2023 Dec 29. doi: 10.1111/pcmr.13156. Online ahead of print.ABSTRACTDacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent therapies. The aim of this study was to investigate the treatment effect of DTIC/TMZ in MM patients after CPI therapy in a consecutive patient cohort and through systematic literature revie...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Viktoria Ryd én Ali Inan El-Naggar Anthoula Koliadi Cecilia Olsson Ladjevardi Evangelos Digkas Antonios Valachis Gustav J Ullenhag Source Type: research
Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study
This study reviewed 26 PMME cases from three medical centers. Hybrid capture-based targeted sequencing of 295 and 1021 genes was performed in 14 and 12 cases, respectively. We found that PMME patients had a relatively low tumor mutation burden (median, 2.88 mutations per Mb) and were simultaneously accompanied by mutations in genes such as KIT (6/26, 23%), TP53 (6/26, 23%), SF3B1 (4/26, 15%), and NRAS (3/26, 12%). KIT, NRAS, and BRAF were mutually exclusive, and SF3B1 co-occurred with KIT mutation and amplification. The most common pathways affected were the mitogen-activated protein kinases and DNA damage response (DDR) p...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Ling Deng Hai-Yun Wang Chun-Fang Hu Xiao-Yun Liu Kuntai Jiang Juan-Juan Yong Xiao-Yan Wu Kai-Hua Guo Fang Wang Source Type: research
Small extracellular vesicle-based human melanocyte and melanoma signature
Pigment Cell Melanoma Res. 2023 Dec 29. doi: 10.1111/pcmr.13158. Online ahead of print.ABSTRACTIntercellular communication is a cell-type and stimulus-dependent event driven not only by soluble factors but also by extracellular vesicles (EVs). EVs include vesicles of different size and origin that contain a myriad of molecules. Among them, small EVs (sEV; <200 nm) have been shown to modulate not just regional cell responses but also distant organ behavior. In cancer, distant organ modulation by sEVs has been associated to disease dissemination, which is one of the main concerns in melanoma. Description of broadly conser...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Andrea Ag üera-Lorente Ainhoa Alonso-Pardavila Mar ía Larrinaga Mar ía Dolores Boyano Esperanza Gonz ález Juan Manuel Falc ón-Pérez Aintzane Asumendi Aintzane Apraiz Source Type: research
Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients
Pigment Cell Melanoma Res. 2023 Dec 28. doi: 10.1111/pcmr.13155. Online ahead of print.ABSTRACTDifferences in survival according to the pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT). A retrospective cross-sectional study including 684 patients was designed, and a Partial Least-Squares Discriminant Analysis (PLS-DA) w...
Source: Pigment Cell and Melanoma Research - December 28, 2023 Category: Cytology Authors: Esperanza Manrique-Silva Mill án-Esteban David Aguerralde-Martin Maider Zaida Garc ía-Casado Ruggero Moro Celia Requena Victor Trav és Amaya Vir ós Rajiv Kumar Eduardo Nagore Source Type: research
Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients
Pigment Cell Melanoma Res. 2023 Dec 28. doi: 10.1111/pcmr.13155. Online ahead of print.ABSTRACTDifferences in survival according to the pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT). A retrospective cross-sectional study including 684 patients was designed, and a Partial Least-Squares Discriminant Analysis (PLS-DA) w...
Source: Pigment Cell and Melanoma Research - December 28, 2023 Category: Cytology Authors: Esperanza Manrique-Silva Mill án-Esteban David Aguerralde-Martin Maider Zaida Garc ía-Casado Ruggero Moro Celia Requena Victor Trav és Amaya Vir ós Rajiv Kumar Eduardo Nagore Source Type: research
Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients
Pigment Cell Melanoma Res. 2023 Dec 28. doi: 10.1111/pcmr.13155. Online ahead of print.ABSTRACTDifferences in survival according to the pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT). A retrospective cross-sectional study including 684 patients was designed, and a Partial Least-Squares Discriminant Analysis (PLS-DA) w...
Source: Pigment Cell and Melanoma Research - December 28, 2023 Category: Cytology Authors: Esperanza Manrique-Silva Mill án-Esteban David Aguerralde-Martin Maider Zaida Garc ía-Casado Ruggero Moro Celia Requena Victor Trav és Amaya Vir ós Rajiv Kumar Eduardo Nagore Source Type: research
Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients
Pigment Cell Melanoma Res. 2023 Dec 28. doi: 10.1111/pcmr.13155. Online ahead of print.ABSTRACTDifferences in survival according to the pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT). A retrospective cross-sectional study including 684 patients was designed, and a Partial Least-Squares Discriminant Analysis (PLS-DA) w...
Source: Pigment Cell and Melanoma Research - December 28, 2023 Category: Cytology Authors: Esperanza Manrique-Silva Mill án-Esteban David Aguerralde-Martin Maider Zaida Garc ía-Casado Ruggero Moro Celia Requena Victor Trav és Amaya Vir ós Rajiv Kumar Eduardo Nagore Source Type: research
Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients
Pigment Cell Melanoma Res. 2023 Dec 28. doi: 10.1111/pcmr.13155. Online ahead of print.ABSTRACTDifferences in survival according to the pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent pTERT mutation subtypes (-124C > T, -146C > T, and tandem -138_139CC > TT). A retrospective cross-sectional study including 684 patients was designed, and a Partial Least-Squares Discriminant Analysis (PLS-DA) w...
Source: Pigment Cell and Melanoma Research - December 28, 2023 Category: Cytology Authors: Esperanza Manrique-Silva Mill án-Esteban David Aguerralde-Martin Maider Zaida Garc ía-Casado Ruggero Moro Celia Requena Victor Trav és Amaya Vir ós Rajiv Kumar Eduardo Nagore Source Type: research
Overview of current melanoma therapies
Pigment Cell Melanoma Res. 2023 Dec 8. doi: 10.1111/pcmr.13154. Online ahead of print.ABSTRACTMelanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.PMID:38063139 | DOI:10.1111/pcmr.13154 (Source: Pig...
Source: Pigment Cell and Melanoma Research - December 8, 2023 Category: Cytology Authors: Anna Fateeva Kevinn Eddy Suzie Chen Source Type: research
Overview of current melanoma therapies
Pigment Cell Melanoma Res. 2023 Dec 8. doi: 10.1111/pcmr.13154. Online ahead of print.ABSTRACTMelanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.PMID:38063139 | DOI:10.1111/pcmr.13154 (Source: Pig...
Source: Pigment Cell and Melanoma Research - December 8, 2023 Category: Cytology Authors: Anna Fateeva Kevinn Eddy Suzie Chen Source Type: research
Overview of current melanoma therapies
Pigment Cell Melanoma Res. 2023 Dec 8. doi: 10.1111/pcmr.13154. Online ahead of print.ABSTRACTMelanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.PMID:38063139 | DOI:10.1111/pcmr.13154 (Source: Pig...
Source: Pigment Cell and Melanoma Research - December 8, 2023 Category: Cytology Authors: Anna Fateeva Kevinn Eddy Suzie Chen Source Type: research
Overview of current melanoma therapies
Pigment Cell Melanoma Res. 2023 Dec 8. doi: 10.1111/pcmr.13154. Online ahead of print.ABSTRACTMelanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.PMID:38063139 | DOI:10.1111/pcmr.13154 (Source: Pig...
Source: Pigment Cell and Melanoma Research - December 8, 2023 Category: Cytology Authors: Anna Fateeva Kevinn Eddy Suzie Chen Source Type: research
